Savara (SVRA) Cash from Operations (2010 - 2026)
Savara (SVRA) posted quarterly Cash from Operations of 33046000.0 for Q1 2026, down 21.54% year-over-year from 42119243.11 in Q1 2025, and down 31.88% quarter-over-quarter from 25057000.0 in Q4 2025.
Savara (SVRA) Cash from Operations (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Cash from Operations for 17 consecutive years, with 33046000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 21.54% year-over-year to 33046000.0; the TTM figure through Mar 2026 stood at 106894000.0 (down 11.78% YoY), while the FY2025 annual figure was 101037000.0, down 13.41% from the prior year.
- Cash from Operations fell to 33046000.0 in Q1 2026 per SVRA's latest filing, from 25057000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8162000.0 in Q3 2022 and bottomed at 33046000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 18163882.35 across 5 years, with a median of 20644000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations increased 23.6% — and 2024, when it slumped 118.99%.
- Savara's Cash from Operations stood at 8651000.0 in 2022, then tumbled by 80.36% to 15603000.0 in 2023, then sank by 49.21% to 23281000.0 in 2024, then declined by 7.63% to 25057000.0 in 2025, then tumbled by 31.88% to 33046000.0 in 2026.
- Business Quant data shows SVRA's Cash from Operations at 33046000.0 in Q1 2026, 25057000.0 in Q4 2025, and 22530000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -29.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.75 Mn |
| Jun 30, 2026 | -29.75 Mn |
| Mar 31, 2026 | -33.05 Mn |
| Mar 31, 2026 | -33.05 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.26 Mn |
| Jun 30, 2025 | -26.26 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Dec 31, 2024 | -23.28 Mn |
| Dec 31, 2024 | -23.28 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Jun 30, 2024 | -22.50 Mn |
| Jun 30, 2024 | -22.50 Mn |
| Mar 31, 2024 | -20.64 Mn |
| Mar 31, 2024 | -20.64 Mn |